Attack phenotypes and disease course in pediatric MOGAD.

Autor: Santoro JD; Division of Neuroimmunology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA.; Department of Neurology, Keck School of Medicine at the University of Southern California, Los Angeles, California, USA., Beukelman T; Epi Excellence LLC, Garnet Valley, Pennsylvania, USA., Hemingway C; Great Ormond Street Hospital for Children, London, UK., Hokkanen SRK; UCB Pharma, Brussels, Belgium., Tennigkeit F; UCB Biosciences, Monheim, Germany., Chitnis T; Department of Neurology, Mass General Brigham, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2023 May; Vol. 10 (5), pp. 672-685. Date of Electronic Publication: 2023 Mar 31.
DOI: 10.1002/acn3.51759
Abstrakt: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune demyelinating condition that affects children differently than adults. We performed a literature review to assess the presentation and clinical course of pediatric MOGAD. The most common initial phenotype is acute disseminated encephalomyelitis, especially among children younger than five years, followed by optic neuritis (ON) and/or transverse myelitis. Approximately one-quarter of children with MOGAD have at least one relapse that typically occurs within three years of disease onset and often includes ON, even if ON was not present at onset. Clinical risk factors for a relapsing course have not been elucidated.
(© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje